SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

Group 1: Chimerix, Inc. - Chimerix, Inc. is being investigated for potential violations of federal securities laws related to its sale to Jazz Pharmaceuticals plc for $8.55 per share in cash [1] - Shareholders of Chimerix are encouraged to learn more about their rights and options regarding the transaction [1] Group 2: GlycoMimetics, Inc. - GlycoMimetics, Inc. is undergoing a merger with Crescent Biopharma, Inc., where GlycoMimetics stockholders are expected to own approximately 3.1% of the combined company upon closing [2] - Shareholders of GlycoMimetics are also encouraged to explore their rights and options concerning the merger [2] Group 3: Legal Representation - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, or other relief on behalf of shareholders [3] - The firm operates on a contingent fee basis, meaning shareholders would not be responsible for out-of-pocket legal fees or expenses [3] - Shareholders are invited to contact the firm free of charge to discuss their legal rights and options [4]